Introduction
Strategies aimed at inducing therapeutic immune responses against tumour cells have focused mainly on T cells, since these represent the immune cell population which exhibit antigen specificity and memory. 1, 2 An effective antitumour lytic response requires activation of pre-cytotoxic CD8 + T cells by cytokines secreted from CD4 + T helper cells which in turn have been activated by professional antigen presenting cells (APCs), such as dendritic cells and macrophages, that have taken up tumour antigens. 3 Professional APCs may also activate CD8 + cytotoxic T cells directly. 4 Activation of T cells requires an antigen-specific signal received by the T cell receptor/CD3 complex, but for efficient and full activation to occur antigen-nonspecific signals are also needed. A crucial costimulatory signal is provided by the CD28 receptor on T cells, 5 the ligands for which belong to the B7 family, including B7-1 (CD80) 6 and B7-2 (B70/CD86). 7, 8 Professional APCs express these B7 costimulatory molecules and thus are capable of presenting antigens to T cells effectively. Costimulatory signals lead to the production of various cytokines which 9 Many human and experimental tumours express specific antigens which may be recognised by T cells and which may act as targets for an immune rejection response. 10 However, as most tumour cells do not express costimulatory molecules, tumour-specific antigens are not presented to T cells efficiently. Indeed, this may represent one mechanism by which tumour cells elude recognition by the immune system. 11 Therefore, costimulatory molecules have been expressed on the surface of tumour cells to enable them to present tumourassociated antigens, together with the costimulatory signal, directly to T cells thus obviating the need for helper T cells and APCs. In support of this model, at least in primary responses against tumours in vivo, some B7-1-expressing tumours have been found to elicit an effective response which is mediated by CD8
+ cells independent of CD4 + cells. 12, 13 Immunotherapy of cancer aims to generate an effective systemic immune response capable of controlling the growth of metastatic tumours. Thus, in addition to the local response against B7-expressing tumours, it is important to determine whether such engineered tumours evoke systemic protective immunity against unmodified tumour cells. In some cases, expression of B7 in poorly immunogenic tumours has been shown to generate systemic immunity, [14] [15] [16] [17] though not in other tumour models. 18, 19 CMT93 murine colorectal tumour is of relatively low intrinsic immunogenicity and previously we demonstrated that expression of B7-1 prevented the growth of the primary tumour, but did not produce a significant increase in the level of systemic immunity, relative to that evoked by the parental tumour. 20 Conversely, expression of B7-1 or B7-2 in another tumour, K1735 murine melanoma, a moderately immunogenic tumour, resulted in retarded growth of the primary tumour, but the systemic immunity elicited was weaker than that generated by the parental tumour. 20 Recently, the ability of B7-expressing tumours to elicit systemic immunity was suggested to be dependent not only on direct antigen presentation to T cells by tumour cells, but also on crosspriming of T cells by host professional APCs. 21, 22 Among possible mechanisms by which the latter route of T cell activation may occur is the suggestion that B7 may activate natural killer cells that then lyse tumour cells, thereby increasing the availability of tumour antigens for uptake by professional APCs. 23 Augmentation of antitumour immune responses might then be obtained by co-expressing B7 with a cytokine which would attract and stimulate other immune effector cells. In this report, we have employed such a combinatorial approach using B7-1 with one of two cytokines. IL-12 is a disulphide-linked heterodimeric cytokine with a broad spectrum of activity which is produced by activated macrophages, B cells and dendritic cells. Among other activities, this cytokine stimulates proliferation and cytotoxic activity of NK cells and T cells. 24 It also induces secretion of a range of cytokines, including interferon-␥, which in turn have various secondary actions. IL-12 cooperates with B7/CD28 costimulation in stimulating lymphocytes in vitro. 25, 26 Moreover, IL-12 has anti-angiogenic properties which may contribute to its antitumour activity. 27 Both subunits of IL-12, p35 and p40 need to be expressed within one cell to obtain biological function, 28 while the p40 subunit alone or as a p40 homodimer may inhibit activity. 29 Indeed, expression of p40, without p35, produces an immunosuppressive effect in vivo. 30, 31 In order to achieve balanced expression of both subunits we have used a bicistronic vector which contains an internal ribosome entry site derived from encephalomyocarditis virus. IL-12 induces a strong local response against a number of tumours, in the context of using recombinant IL-12 32 paracrine secretion at the tumour site using engineered fibroblasts or transfected tumour cells, 33, 34 as well as direct in vivo gene delivery. 31, [35] [36] [37] It also elicits protective immunity against poorly immunogenic tumours and was effective in causing regression of pre-established tumours. 33, 34 GM-CSF stimulates maturation of dendritic cells 38 and up-regulates the surface expression of costimulatory molecules, 39 thus enhancing the antigen-presentation efficiency of APCs. This might be especially useful for eliciting responses against tumour cells which express low levels of MHC class I, since these are unable to present tumour antigens adequately by themselves. 40 Indeed, GM-CSF is particularly effective in generating systemic immunity against a number of poorly immunogenic tumours. [41] [42] [43] It is expected that the combination of B7 costimulation and GM-CSF would be especially beneficial, since each promotes one of the two main routes by which activation of cytotoxic T cells occurs -direct antigen presentation and crosspriming by professional APCs.
In this report, we extend our previous findings on the use of B7 molecules for therapeutic applications. We have examined the effects of the immunostimulatory molecules on local tumour growth and the generation of systemic protective immunity. The latter was assessed by rechallenging with parental tumour cells animals which had previously been inoculated with live engineered tumour cells. Live cells were used for the primary inoculation because of their superior efficacy over nonreplicating cells in evoking systemic responses. [44] [45] [46] We examined the effects of B7-2 expression in CMT93 tumours and in an attempt to potentiate the effects of B7-1 on systemic immunity, B7-1 was co-expressed with IL-12 or GM-CSF. The consequence of co-expressing B7-1 with these cytokines was also investigated in the K1735 tumour model. The results presented here suggest that combining expression of B7 with cytokines may be a potentially useful therapeutic approach in certain tumours, but may be of limited benefit in others.
Results
Expression of B7-2 decreased the tumourigenicity of CMT93 colorectal tumour cells in immunocompetent animals Murine B7-2 (B70/CD86) was expressed in CMT93 colorectal tumour cells using the plasmid BCMGSNeo-mB70 and expression was detected by staining with mCTLA4-H␥1 ( Figure 1 ) or a B7-2-specific monoclonal antibody (data not shown). When injected into immunocompetent syngeneic animals, CMT93 B7-2 cells formed tumours less readily compared with CMT93 cells bearing the 'empty' expression vector. Only half the number of mice given the B7-2-expressing cells developed tumours and these tumours appeared relatively late ( Figure 2 ) (P Ͻ 0.001, stratified log rank test). In athymic T cell-immunodeficient nude mice, CMT93 B7-2 cells grew at the same rate as the parental cells (data not shown), suggesting that T cells mediated the antitumour response in immunocompetent mice.
Expression of B7-2 in CMT93 cells elicited systemic protective immunity Systemic immunity to parental tumour cell rechallenge was examined in mice which had rejected the primary inoculation of CMT93 B7-2 cells, as well as those which had developed progressive tumours that needed surgical excision. A majority of the animals were found to be protected against the rechallenge and this represents a significant increase in protection compared with animals which had been inoculated initially with control CMT93 cells bearing the empty vector ( Figure 3 ) (P Ͻ 0.05, stratified log rank test). cells were injected into immunocompetent animals, tumours failed to develop in all cases ( Figure 4a ). In contrast, tumours were established readily when the IL-12-secreting cells were injected into nude mice, indicating that T cells were necessary for the antitumour response to be effective ( Figure 4b ).
CMT93 cells which co-express B7-1 and IL-12 generated systemic protective immunity Animals which had rejected CMT93 B7-1/IL-12 cells were rechallenged subsequently with parental CMT93 cells in the opposite flank. These mice showed a significantly increased level of protection compared with mice which had been given parental CMT93 cells initially and had tumours that required excision ( Figure 5 ) (P Ͻ 0.02, stratified log rank test). In the group which had received a primary inoculation of CMT93 B7-1 cells, there was a tendency to improved protection compared with mice which had primary parental tumours but, consistent with our previous findings, 20 analysis of data from independent repeated experiments failed to indicate that this increase was significant. Similarly, mice which had been injected initially with CMT93 IL-12 cells (not coexpressing B7-1) also showed a trend to enhanced protection, but this did not reach a level of significance. CMT93 cells which co-express B7-1 and GM-CSF, or expressed GM-CSF only, were poorly tumourigenic in immunocompetent mice GM-CSF was expressed in parental CMT93 cells and CMT93 B7-1 cells using the retroviral vector, pBabeNeo GM-CSF. The clones used in these experiments produced 1.3 and 2.6 ng/10 6 cells per 48 h of GM-CSF, respectively. Progressively growing tumours did not develop when CMT93 B7-1/GM-CSF cells were injected into immunocompetent mice ( Figure 6 ). Expression of GM-CSF alone also resulted in reduction of tumourigenicity.
CMT93 cells which co-express B7-1 and GM-CSF elicited systemic protective immunity Animals which had received a primary inoculation of CMT93 B7-1/GM-CSF cells were rechallenged sub- sequently with parental cells. These animals showed a clear improvement in protection compared with those which had received primary parental cells (P Ͻ 0.05, stratified log rank test) ( Figure 7 ). The protection offered by CMT93 cells expressing GM-CSF, without B7-1, was inconsistent. In the experiment depicted in Figure 7 , there was a tendency towards protection but this did not reach statistical significance, while in an independent repeated experiment, these cells did elicit a significant increase in protection (data not shown).
Splenocytes from animals which had been inoculated with parental or engineered CMT93 cells secreted a Th1 pattern of cytokines Spleen cells were recovered from mice which had been inoculated 6 weeks previously with parental CMT93 cells or cells expressing B7-1, IL-12, B7-1/IL-12, GM-CSF or B7-1/GM-CSF. Mice injected with the parental cells developed tumours and these were excised. Spleen cells were also obtained from mice which had not been inoculated (naive mice). The spleen cells were cocultured with mitomycin C-treated CMT93 cells for 5 days and quantities of the following secreted cytokines were determined: IL-2, IL-4, IL-12, interferon-␥ and GM-CSF. For each experiment, spleen cells from two mice of each group were pooled. Figure 8 shows the results obtained from three independent sets of experiments (in total, three pairs of mice for each group). Neither IL-2 nor IL-4 was detected in all cases (data not shown), whereas IL-12 was secreted by cells from all groups. There was no corre- lation between the amount of IL-12 produced and the in vivo tumourigenicity of the various engineered cells or their ability to elicit protective immunity. Spleen cells from all groups also produced GM-CSF and interferon-␥, except cells from naive mice which consistently failed to produce detectable levels of these cytokines. Among the other groups, there was no pattern of correlation with the in vivo data. Mice which had rejected K1735 B7-1/IL-12 cells or K1735 IL-12 cells were not protected against parental cell rechallenge Mice which had rejected the initial inoculation of K1735 B7-1/IL-12 cells or K1735 IL-12 cells were rechallenged with parental cells. Tumours resulted in most of these animals and, although there was a delay in the appearance of the tumours relative to naive control mice, this represented less resistance compared with animals which had borne established primary parental tumours ( Figure 10 ).
Expression of GM-CSF in K1735 cells, or co-expression of B7-1 and GM-CSF, resulted in delayed growth of primary tumours
Expression of GM-CSF in parental K1735 cells and K1735 B7-1 cells was achieved using the pBabeNeo GM-CSF retroviral vector. The clones used in this study secreted 
and 8.3 ng/10
6 cells per 48 h of GM-CSF, respectively. Tumours developed in most cases when these cells were injected into immunocompetent mice, although there was a delay in the appearance of these tumours relative to those arising from parental cells (Figure 11 ).
K1735 cells which express GM-CSF alone elicited protective immunity against parental cell rechallenge, while K1735 cells which co-express B7-1 and GM-CSF generated less immunity Mice which had been inoculated initially with K1735 cells which express GM-CSF, without B7-1, were protected against rechallenge, to a degree similar to that elicited by the parental tumours themselves (Figure 12 ). Previously, we reported that K1735 B7-1 generated a lower level of protection compared with that produced by the parental tumours. 20 Co-expression of GM-CSF with B7-1 failed to improve the level of protective immunity. 
Discussion
Some controversy exists as to the relative functional activities of B7-1 and B7-2. 47 In a number of in vivo and in vitro studies, B7-1 and B7-2 were found to favour secretion of different profiles of cytokines, [48] [49] [50] though other studies have not found any differences. [51] [52] [53] Expression of B7-2 in CMT93 colorectal tumour cells resulted in a decrease in their tumourigenicity, similar to the effects of B7-1 expression we had described previously. 20 However, unlike B7-1, the B7-2-expressing cells induced a significant degree of protective immunity relative to that elicited by the parental tumour. The clones of B7-1 and B7-2 cells used in these studies expressed similar levels of the costimulatory molecule. Although B7-2 appeared to be superior in generating protective immunity in this tumour, this is not true for all tumours. Where these two costimulatory molecules have been compared, their effects have been found to be equal in some cases, 54 while in others, either B7-1 17, 55 or B7- 2 16 was more potent. Although expression of B7-1 in CMT93 tumours was effective in inducing a local rejection response against the primary tumour, this did not generate a significantly increased level of systemic immunity relative to that evoked by the parental tumour. 20 In an attempt to augment this response, B7-1 was co-expressed with either IL-12 or GM-CSF. IL-12 was selected for its pleiotropic effects on a variety of immune cell types and also because B7-1 and IL-12 co-operate in stimulating lymphocyte proliferation and activation in vitro. 25, 26 GM-CSF was used since it is involved crucially in the maturation of professional APCs, and crosspriming by these cells was expected to complement the ability of B7-expressing tumour cells to present antigens directly to T cells. Indeed, CMT93 cells which co-expressed B7-1 and one of these cytokines were found consistently to lead to a significant improvement in systemic protection.
The cytokine secretion profiles of spleen cells were examined 6 weeks after inoculation with tumour cells. IL-2 and IL-4 were not detected in these assays, whereas IL-12 was present in all cases. The presence of IL-12 may reflect constitutive production by macrophages within the spleen cell population. Interferon-␥ and GM-CSF were not released by splenocytes from naive mice, but were produced by splenocytes from all the other groups, including mice which had been inoculated with parental tumour cells. This correlates with the observation that under the experimental conditions used here even the parental cells showed a tendency to elicit resistance against rechallenge (Figures 3 and 5 , and data not shown). However, amongst the various groups which had been inoculated, there was no correlation of cytokine production with levels of systemic immunity.
Previously, we reported that even though expression of B7-1 in K1735 melanoma caused the primary tumours to grow more slowly, the protective immunity induced by these tumours was inferior to that elicited by parental tumours. 20 Expression of GM-CSF alone generated a level of protective immunity similar to that produced by the parental tumours but when co-expressed with B7-1, GM-CSF failed to reverse the inhibitory effect of B7-1. The basis of this B7-1-mediated reduction in protective immunity is unclear and thus it is difficult to explain the failure of GM-CSF to improve immunity in this situation. However, one difference between the K1735 and CMT93 tumours which may be of significance and which may contribute to the different effects of B7-1 in these tumours, is that CMT93 cells express surface MHC class I molecules, whereas these are undetectable on K1735 cells. As such, K1735 cells which express B7-1 may still be inefficient at presenting antigens to T cells directly.
IL-12, with or without B7-1, was powerful in abrogating the growth of K1735 cells completely. No tumours developed even when the cell inoculum was increased by 10-fold that of the parental minimal tumourigenic dose. However, mice which had rejected IL-12-secreting K1735 cells showed little protection against parental cell rechallenge although, compared with naive mice, there was a clear delay in the emergence of the tumours (Figure 10 ). Why the IL-12-secreting cells were weak at generating protective immunity, in spite of their potent effects against the primary inoculation of tumour cells, is uncertain. Since these cells were rejected, the quantity of tumour antigens to which the host was exposed would be very low compared with mice injected with parental K1735 cells, in which progressively growing tumour masses were established. Possibly, IL-12-secreting K1735 cells in the primary challenge induced a particularly strong local response, including 'nonspecific' effector cells such as NK cells, which may result in such early elimination of tumour cells as to prevent sufficient time for necessary interaction with T cells. In support of this possibility is the observation that when IL-12-secreting K1735 cells were injected into nude mice, there was a marked delay in the emergence of tumours compared with mice given parental cells (Figure 9b ), indicating that non-T effector cells, such as NK cells, must have participated in the initial reaction against the IL-12-secreting cells. This contrasts with the situation in the CMT93 tumour model, where IL-12-producing cells grew readily in nude mice (Figure 4b) suggesting that in this instance T cells were involved in the early reaction against these cells in immunocompetent mice. Interestingly, others have recently reported that co-expression of B7-1 and IL-2 in another tumour resulted in brisk rejection of the cells but that the systemic immunity elicited was relatively weak. 56 This situation bears some similarities with our results with IL-12-secreting K1735 cells.
The combination of B7-1 and IL-12 was effective in generating systemic immunity in other models. Thus, B7-1-expressing tumour cells co-injected with an equal number of IL-12-secreting tumour cells or fibroblasts, 57 or B7-1-expressing tumour cells together with recombinant IL-12, 58 both elicited systemic immunity. These approaches contrasted with ours where we employed tumour cells which were engineered to co-express B7-1 and IL-12.
More comparable with our experiments, the advantages of co-expressing B7-1 with IL-12, 59 or B7-2 with GM-CSF, 60 have also been reported, but in these cases the effects on systemic immunity of expressing B7 or the cytokine alone were not determined. Therefore, it is difficult to ascribe these findings to the combined effect of these molecules. Our study differed in that we also investigated the effects of expressing B7, IL-12 and GM-CSF separately as well as in combination.
The effects of co-expressing B7-1 with other cytokines have also been examined. The combination of B7-1 and IL-2 was effective in reducing tumourigenicity, 61 but an unexpected effect of this combination on systemic immunity was noted, as discussed above.
56 B7-1 has also been combined with IL-4 62 or IL-7 45 and in these cases better protective immunity was generated compared with any of these molecules alone.
We show here that it was possible to improve the ability of B7-1-expressing CMT93 tumour cells to generate systemic immunity by co-expression of cytokines. The choice of cytokines was based on properties which were predicted to complement those of the B7-1 cells. Expression of B7-1 was expected to make tumour cells competent at direct antigen presentation to T cells, while co-expression of the cytokine would enhance activation of T cells and other effector cells and promote crosspriming by professional APCs. Therefore, combinations of costimulatory molecules and cytokines represent a strategy which could be exploited for therapeutic applications, although our results with the K1735 tumour suggest that such an approach may not always be useful nor does efficacy in stimulating local responses necessarily correlate with ability in generating effective protective immunity. Experiments involving direct delivery of such combinations of immunostimulatory genes to established tumours in vivo are currently underway to evaluate their usefulness for inducing rejection of pre-established tumours and their efficacy in eliciting systemic immunity in this context.
Materials and methods
Cell lines K1735 murine melanoma cells and CMT93 murine colorectal tumour cells engineered to express B7-1 have been described previously. 20 All cell lines were grown in Dulbecco's modified Eagle's minimal essential medium supplemented with 10% (vol/vol) foetal calf serum.
Expression plasmids and retroviral vectors
Subcloning was performed using standard recombinant DNA techniques. 63 The expression vector BCMGSNeomB70 was a kind gift of Dr M Azuma. 8 Plasmid pCR3-IL-12 is a bicistronic expression vector based on the pCR3 vector (Invitrogen NV, Leek, The Netherlands) in which the p35 and p40 subunits of IL-12 are linked by the IRES sequence of the encephalomyocarditis virus, excised from the pCITE-1 vector (Novagen, Madison, WI, USA). The IL-12 subunits were generously provided by HoffmannLa Roche (Nutley, NJ, USA). Transfection was performed by calcium phosphate precipitation, as described previously. 20 The retroviral vector, pBabeNeo GM-CSF, was constructed from the pBabeNeo vector. 64 Production of vectors and infection of cell lines have been described previously. 65 Briefly, vector plasmid was transfected into GP+envAM12 packaging cells 66 and after incubation in selection medium for 3 weeks, surviving colonies were pooled and viral supernatant was harvested and used to infect target cells. Selection media contained 1.25 g/ml puromycin (Sigma, Poole, UK) or 1 mg/ml G418 (Gibco, Paisley, UK). In all cases, compared with the parental lines, the engineered cell lines had similar morphology and growth rates in vitro.
Flow cytometry
Detection of B7-2 expression by staining with the fusion protein mCTLA4-Hg1 (a gift from Dr P Lane 67 ) or GL1 antibody, rat IgG 2a (anti-B7-2; Pharmingen, Cambridge Bioscience, Cambridge, UK) has been described previously. 20 Detection of GM-CSF production from cell lines Infected cell lines (10 6 cells) were seeded in normal medium and 48 h later, the supernatant was harvested and the cells trypsinized and counted. GM-CSF was assayed by ELISA using antibody pairs obtained from Pharmingen.
Functional assay for detection and quantification of interleukin-12 IL-12 was quantified using an assay based on the ability of this cytokine to stimulate production of interferon-␥ by lymphocytes. Fresh splenocytes (2.5 × 10 6 cells in 0.5-ml aliquots) were placed in wells with 0.5 ml of the test supernatant. A range of diluted recombinant IL-12 (Pharmingen) was used as standards. After incubation for 48 h, the supernatant was assayed for interferon-␥ by ELISA, using antibody pairs (Pharmingen). The assay for IL-12 was quantified by comparing the amount of interferon-␥ produced in the test samples with that induced by the recombinant IL-12 standards.
Detection of cytokines secreted by splenocytes in vitro
Fresh spleen cells were obtained from naive mice or mice which had been inoculated with a variety of engineered CMT93 cells. Spleen cells (5 × 10 6 cells) were mixed with mitomycin C-treated CMT93 cells (1 × 10 5 cells) in 2-ml volumes and incubated for 5 days. The spleen cells were then counted and the supernatant assayed for IL-2, IL-4, IL-12, GM-CSF and interferon-␥ by ELISA, using antibody pairs (Pharmingen).
In vivo injection of tumour cells C3H/HeN mice, C57BL/6 mice and BALB/c nude mice were obtained from colonies bred at the Imperial Cancer Research Fund. Mice were age-and sex-matched for individual experiments. To establish subcutaneous tumours, 5 × 10 5 K1735 cells or 5 × 10 6 CMT93 cells were injected s.c. (100 l) into the flank region. Animals were examined daily until the tumour became palpable, whereafter the diameter in two dimensions was measured three times a week. Animals were killed or had tumours surgically excised (see below), when tumour size was approximately 1.0 × 1.0 cm.
Rechallenge of mice
After tumour excision mice were rechallenged with s.c. injection of 5 × 10 5 parental K1735 cells or 2 × 10 6 parental CMT93 cells on the opposite flank. Mice which had rejected the initial inoculation of tumour cells were also rechallenged. All groups of mice in any one individual experiment were rechallenged using the same preparation of cells on the same occasion, 7-10 days following the most recent surgical excision that had been performed on any mouse in the cohort. A naive group of mice was also injected with these cells at the same time. Animals were monitored as described above.
Statistical analyses of in vivo experiments
Data from animal experiments were analyzed by plotting Kaplan-Meier curves using the 'occurring event' as the time at which a tumour appeared. A tumour was considered present when a palpable mass Ͼ0.2 cm was noted. Comparisons were made using the log rank test. Data from independent experiments were combined by using the stratified log rank test to obtain a more sensitive comparison. 68 
